Treatment strategy for medullary thyroid cancer

Abstract

Bi Yalan, Meng Yunxiao, Cui Quancai. Treatment strategy for medullary thyroid cancer[J]. Journal of International Oncology, 2014, 41(8): 582-585.

［1］ Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments［J］. Curr Opin Oncol, 2011, 23(1): 22-27. ［2］ Figlioli G, Landi S, Romei C, et al. Medullary thyroid carcinoma (MTC) and RET protooncogene: mutation spectrum in the familial cases and a metaanalysis of studies on the sporadic form［J］. Mutat Res, 2013, 752(1): 36-44. ［3］ Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 yearsexperience on 157 patients［J］. Eur J Surg Oncol, 2007, 33(4): 493-497. ［4］ Stamatakos M, Paraskeva P, Katsaronis P, et al. Surgical approach to the management of medullary thyroid cancer: when is lymph node dissection needed?［J］ . Oncology, 2013, 84(6): 350-355. ［5］ Kandil E, Gilson MM, Alabbas HH, et al. Survival implications of cervical lymphadenectomy in patients with medullary thyroid cancer［J］. Ann Surg Oncol, 2011, 18(4): 1028-1034. ［6］ Dequanter D, Lothaire P. Medullary thyroid cancer: surgical results and prognostic factors［J］. Rev Med Liege, 2010, 65(7-8): 450-452. ［7］ Machens A, Hauptmann S, Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer［J］. Br J Surg, 2008, 95(5): 586-591. ［8］ American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association［J］. Thyroid, 2009, 19(6): 565-612. ［9］ Sugawara M, Ly T, Hershman JM. Medullary thyroid cancercurrent treatment strategy, novel therapies and perspectives for the future［J］. Horm Cancer, 2012, 3(56): 218-226. ［10］ Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases［J］. Cancer, 2006, 107(9): 2134-2142. ［11］ Meijer JA, le Cessie S, van den HoutWB, et al. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured metaanalysis［J］. Clin Endocrinol(Oxf), 2010, 72(4): 534-542. ［12］ Sugawara M, Geffner DL, Martinez D, et al. Novel treatment of medullary thyroid cancer［J］. Curr Opin Endocrinol Diabetes Obes, 2009, 16(5): 367372. ［13］ Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10year followup study［J］. J Clin Endocrinol Metab, 2008, 93(3): 682-687. ［14］ Capp C, Wajner SM, Siqueira DR, et al. Increased expression of vascular endothelial growth factor and its receptors, VEGFR1 and VEGFR2, in medullary thyroid carcinoma［J］. Thyroid, 2010, 20(8): 863-871. ［15］ Campbell MJ, Seib CD, Gosnell J. Vandetanib and the management of advanced medullary thyroid cancer［J］. Curr Opin Oncol, 2013, 25(1): 39-43. ［16］ Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, doubleblind phase Ⅲ trial［J］. J Clin Oncol, 2012, 30(2): 134-141. ［17］ Haraldsdottir S, Shah MH. An update on clinical trials of targeted therapies in thyroid cancer［J］. Curr Opin Oncol, 2014, 26(1): 36-44. ［18］ Bodei L, HandkiewiczJunak D, Grana C, et al. Receptor radionuclide therapy with 90YDOTATOC in patients with medullary thyroid carcinomas［J］. Cancer Biother Radiopharm, 2004, 19(1): 65-71. ［19］ Vainas I, Koussis Ch, PazaitouPanayiotou K, et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma［J］. J Exp Clin Cancer Res, 2004, 23(4): 549-559. ［20］ Vitale G, Lupoli G, Guarrasi R, et al. Interleukin2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies［J］. J Clin Endocrinol Metab, 2013, 98(10): E1567-1574. ［21］ Martinez SR, Beal SH, Chen A, et al. Adjuvant external beam radiation for medullary thyroid carcinoma［J］. J Surg Oncol, 2010, 102(2): 175-178. ［22］ Schwartz DL, Rana V, Shaw S, et al. Postoperative radiotherapy for advanced medullary thyroid cancerlocal disease control in the modern era［J］. Head Neck, 2008, 30(7): 883-888.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Qian Xiaotao, Shi Ziyi, Hu Ge.A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(3): 151-156.
[8]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing.Progress of radiotherapy in oligometastatic non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(3): 170-174.
[9]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei.Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients[J]. Journal of International Oncology, 2024, 51(1): 37-42.
[10]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[11]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[12]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway[J]. Journal of International Oncology, 2023, 50(7): 398-406.
[13]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[14]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[15]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.

Treatment strategy for medullary thyroid cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments